Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: Risk factor analysis from a nationwide population-based study

Osteoporosis International

Volumn 25, Issue 5, 2014, Pages 1617-1623

  Peng, Y L ^a,b   Hu, H Y ^a,c   Luo, J C ^a,b   Hou, M C ^a,b   Lin, H C ^a,b   Lee, F Y ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Alendronate; Co morbidities; Lower gastrointestinal bleeding; Upper gastrointestinal bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; CLOPIDOGREL; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; STEROID; TICLOPIDINE; WARFARIN; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PEPTIC ULCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UPPER GASTROINTESTINAL BLEEDING; AGE; CASE CONTROL STUDY; CHEMICALLY INDUCED; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; SEX DIFFERENCE; TAIWAN; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALENDRONATE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; SEX FACTORS; TAIWAN;

EID: 84899646733     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2647-z     Document Type: Article

References (18)

1. Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2011) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871-1880
2. Lewiecki EM (2011) Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drug 71:791-814
3. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2006) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517-525
4. Etminan M, Lévesque L, Fitzgerald JM (2009) Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study. Aliment Pharmacol Ther 29:1188-1192
5. Knopp-Sihota JA, Cummings GG, Homik J, Voaklander D (2013) The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study. BMC Geriatr 13:36 [Epub ahead of print]
6. Luo JC, Leu HB, Huang N, KW Huang CC, Hou MC, Lin HC, Lee FY, Lee SD (2011) Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ 183:E1345-E1351
7. Luo JC, Leu HB, Hou MC, Huang KW, Lin HC, Lee FY, Chan WL, Lin SJ, Chen JW (2013) Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients. Am J Med 126(264):e25-e32
8. Lin CC, Hu HY, Luo JC, Peng YL, Hou MC, Lin HC, Lee FY (2013) Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study. Aliment Pharmacol Ther 38:1119-1128
9. Miyake K, Kusunoki M, Shinji Y, Shindo T, Kawagoe T, Futagami S, Gudis K, Tsukui T, Nakajima A, Sakamoto C (2009) Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol 44:113-120
10. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021
11. Graham DY, Malaty HM (1999) Alendronate gastric ulcers. Aliment Pharmacol Ther 13:515-519
12. Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, Buist DS, Carey VJ, Chandler JM, Chase GA, Ettinger B, Fishman P, Goodman M, Guess HA, Gurwitz JH, LaCroix AZ, Levin TR, Platt R (2002) Gastric and duodenal safety of daily alendronate. Arch Intern Med 162:936-942
13. Lichtenberger LM, Romeo JJ, Gibson GW, Blank MA (2000) Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45:1792-1801
14. Luckman SP, Hughes DE, Coxon EP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding protein, including rats. J Bone Miner Res 13:581-589
15. Takeuchi K, Kato S, Amagase K (2011) Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate- prophylactic effects of rebamipide. Curr Pharm Des 17:1602-1611
16. Amagase K, Hayashi S, Nishikawa K, Aihara E, Takeuchi K (2007) Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. Dig Dis Sci 52:1879-1889
17. Luo JC, Huo TI, Hou MC, Lin HY, Li CP, Lin HC, Chang FY, Lee FY (2012) Clopidogrel delays gastric ulcer healing in rats. Eur J Pharmacol 695:112-119
18. Huang KW, Luo JC, Leu HB, Huang CC, Hou MC, Chen TS, Lu CL, Lin HC, Lee FY, Chang FY (2013) Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel. J Chin Med Assoc 76:9-14